CF PharmTech, Inc. reported no change in its total registered share capital for February 2026, maintaining 302.22 million H shares and 109.75 million Domestic Shares at a par value of RMB 1 each, reaching a combined total of RMB 411.98 million. The count of H shares issued (excluding treasury shares) decreased by 0.33 million, bringing the total to 301.73 million, while treasury shares rose to 0.50 million.

According to the announcement, the company’s minimum prescribed public float requirement remains at 24.70% for its H shares, and it confirms compliance with that threshold as at the reporting date. There were no other share issuances, conversions, or transfers during the month aside from the noted repurchase activity. Domestic Shares stood unchanged at 109.75 million. All activities were duly authorized and met applicable regulatory requirements.